In particular, UAD represents a strong factor with comorbid CRSwNP-SA, defining a particular eosinophilic condition for which anti–IL-5 biologics have increased efficacy and should be managed through a collaborative and multidisciplinary approach (108). This evidence concerns the gene IL5 and urethra adenocarcinoma.